rs138069616
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_000492.4(CFTR):c.2392C>T(p.Pro798Ser) variant causes a missense change. The variant allele was found at a frequency of 0.0000441 in 1,520,656 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P798L) has been classified as Uncertain significance.
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.2392C>T | p.Pro798Ser | missense_variant | 14/27 | ENST00000003084.11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.2392C>T | p.Pro798Ser | missense_variant | 14/27 | 1 | NM_000492.4 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152196Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000111 AC: 2AN: 180160Hom.: 0 AF XY: 0.0000105 AC XY: 1AN XY: 94956
GnomAD4 exome AF: 0.0000468 AC: 64AN: 1368460Hom.: 0 Cov.: 32 AF XY: 0.0000358 AC XY: 24AN XY: 671326
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152196Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74368
ClinVar
Submissions by phenotype
Cystic fibrosis Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Sep 05, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 07, 2022 | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 798 of the CFTR protein (p.Pro798Ser). This variant is present in population databases (rs138069616, gnomAD 0.005%). This missense change has been observed in individual(s) with CFTR-related conditions (PMID: 25735457). ClinVar contains an entry for this variant (Variation ID: 35841). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 23, 2023 | The p.P798S variant (also known as c.2392C>T), located in coding exon 14 of the CFTR gene, results from a C to T substitution at nucleotide position 2392. The proline at codon 798 is replaced by serine, an amino acid with similar properties. An individual diagnosed with cystic fibrosis was reported to be heterozygous for this variant, in addition to the p.F508del pathogenic mutation and three other variants of unknown significance (p.R74W, p.D1270N, p.G921E). The phase (cis vs trans) of these alterations was not determined (Sharma G, Pediatr. Pulmonol. 2013 Mar; 48(3):236-44). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Jun 15, 2022 | CFTR c.2392C>T has been identified in multiple individuals with features of cystic fibrosis; however, each individual carries multiple CFTR variants and the contribution of this variant to their phenotype is uncertain. This CFTR variant (rs138069616) is rare (<0.1%) in a large population dataset (gnomAD: 2/180160 total alleles; 0.001%; no homozygotes) and it has been reported in ClinVar (Variation ID: 35841). Of three bioinformatics tools queried, two predict that this substitution would be tolerated, while one predicts that it would be damaging. The proline residue at this position is conserved in most species assessed, although a serine is present at this position in Xenopus tropicalis. We consider the clinical significance of CFTR c.2392C>T to be uncertain at this time. - |
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 29, 2020 | The CFTR c.2392C>T; p.Pro798Ser variant (rs138069616) is reported in the literature in one individual with cystic fibrosis who also carried additional pathogenic variants (Sharma 2013), but the phase and significance of the variants were not determined. The variant is reported in the ClinVar database (Variation ID: 35841) and is listed in the general population with an overall allele frequency of 0.001% (2/180,160 alleles) in the Genome Aggregation Database. The proline at codon 798 is moderately conserved and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Due to limited information, the clinical significance of the p.Pro798Ser variant is uncertain at this time. References: Sharma G et al. Reduced Arylsulfatase B Activity in Leukocytes From Cystic Fibrosis Patients. Pediatr Pulmonol. 2013 Mar;48(3):236-44. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 27, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 17, 2023 | Identified in a patient with cystic fibrosis in published literature; however, this individual also harbored several other CFTR variants of unknown phase (Sharma et al., 2013); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25735457, 22550062) - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 23, 2022 | Variant summary: CFTR c.2392C>T (p.Pro798Ser) results in a non-conservative amino acid change located in the CFTR regulator domain (IPR025837) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.1e-05 in 180160 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.2392C>T has been observed in an internal specimen in cis with R74W, D1270N, and G921E (all paternally inherited) in a child diagnosed with Cystic Fibrosis (CF), who carried the common disease variant, F508del, in trans. This complex genotype (phase not specified) has also been reported in the literature in an individual affected with CF (Sharma_2013). The co-occurring complex allele, c.[220C>T;3808G>A] (p.[Arg74Trp;Asp1270Asn]), has been classified as a VUS-possibly pathogenic variant by our laboratory (Variation ID: 977735). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
CFTR-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 14, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at